The local effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) on the inflammatory atheroma: beyond LDL cholesterol lowering

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has gained extensive attention since the discovery of its role in mediating hepatic low-density lipoprotein (LDL)-receptor (LDLR) degradation, and therefore regulating plasma LDL cholesterol clearance. However, emerging studies have indicated that PCSK9 may have pleiotropic effects on the development of atherosclerosis and eventually cardiac dysfunction by mechanisms independent of the regulation of LDL cholesterol levels. In this review, we will discuss recent findings of how PCSK9 affects cellular responses and the pro-inflammatory microenvironment within the local atherosclerotic vascular wall, which are critical for atherosclerotic plaque progression. We will also discuss recent research on the potential direct effects of PCSK9 on cardiomyocyte viability and function. These pathways may be critical for understanding the mechanisms of PCSK9’s cardioprotective effects beyond LDL cholesterol lowering.

Keywords

Atherosclerosis / inflammation / myocardial infarction / PCSK9

References

[1] Roth GA,Abate KH.Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017..Lancet2018;392:1736-88 PMCID:PMC6227606

[2] Gaziano TA,Anand S,Murphy A.Growing epidemic of coronary heart disease in low- and middle-income countries..Curr Probl Cardiol2010;35:72-115 PMCID:PMC2864143

[3] Cunningham KS.The role of shear stress in the pathogenesis of atherosclerosis..Lab Investig2005;85:9-23

[4] Moore KJ,Fisher EA.Macrophages in atherosclerosis: a dynamic balance..Nat Rev Immunol2013;13:709-21 PMCID:PMC4357520

[5] Shankman LS,Cherepanova OA.KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis..Nat Med2015;21:628-37 PMCID:PMC4552085

[6] Wang Y,Allahverdian S.Smooth muscle cells contribute the majority of foam cells in ApoE (Apolipoprotein E)-deficient mouse atherosclerosis..Arterioscler Thromb Vasc Biol2019;39:876-87 PMCID:PMC6482082

[7] Gonzalez L.Macrophage apoptosis and necrotic core development in atherosclerosis: a rapidly advancing field with clinical relevance to imaging and therapy..Can J Cardiol2017;33:303-12

[8] Maron DJ,Linton MF.Current perspectives on statins..Circulation2000;101:207-13

[9] Davidson MH.Reducing residual risk for patients on statin therapy: the potential role of combination therapy..Am J Cardiol2005;96:3K-13Kdiscussion 34K-35K

[10] Ridker PM,Thuren T.Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease..N Engl J Med2017;377:1119-31

[11] Benjannet S,Essalmani R.NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol..J Biol Chem2004;279:48865-75

[12] Sahng WP,Horton JD.Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver..J Biol Chem2004;279:50630-8

[13] Sabatine MS,Keech AC.Evolocumab and clinical outcomes in patients with cardiovascular disease..N Engl J Med2017;376:1713-22

[14] Schwartz GG,Szarek M.Alirocumab and cardiovascular outcomes after acute coronary syndrome..N Engl J Med2018;379:2097-107

[15] Silverman MG,Im K.Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis..JAMA2016;316:1289-97

[16] Leander K,Van’t Hooft FM.Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors..Circulation2016;133:1230-9

[17] Karagiannis AD,Toth PP.Pleiotropic anti-atherosclerotic effects of PCSK9 inhibitorsfrom molecular biology to clinical translation..Curr Atheroscler Rep2018;20:20

[18] Tang ZH,Ren Z.New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway..Atherosclerosis2017;262:113-22

[19] Giunzioni I,Covarrubias R.Local effects of human PCSK9 on the atherosclerotic lesion..J Pathol2016;238:52-62 PMCID:PMC5346023

[20] Denis M,Zaid A.Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice..Circulation2012;125:894-901

[21] Tavori H,Predazzi IM.Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms..Cardiovasc Res2016;110:268-78 PMCID:PMC4836631

[22] Ferri N,Tibolla G.PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement..Atherosclerosis2016;253:214-24

[23] Zernecke A,Cochain C.Meta-analysis of leukocyte diversity in atherosclerotic mouse aortas..Circ Res2020;127:402-26 PMCID:PMC7371244

[24] Malek AM.Hemodynamic Shear stress and its role in atherosclerosis..JAMA1999;282:2035

[25] Gimbrone MA Jr.Endothelial cell dysfunction and the pathobiology of atherosclerosis..Circ Res2016;118:620-36 PMCID:PMC4762052

[26] Iiyama K,Iiyama M.Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation..Circ Res1999;85:199-207

[27] Ley K,Cybulsky MI.Getting to the site of inflammation: the leukocyte adhesion cascade updated..Nat Rev Immunol2007;7:678-89

[28] Hsu S,Chen FF,Li S.Effects of fluid shear stress on a distinct population of vascular smooth muscle cells..Cell Mol Bioeng2011;4:627-36 PMCID:PMC3425612

[29] Wirka RC,Paik DT.Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis..Nat Med2019;25:1280-9 PMCID:PMC7274198

[30] Gomez D.Smooth muscle cell phenotypic switching in atherosclerosis..Cardiovasc Res2012;95:156-64 PMCID:PMC3388816

[31] Bennett MR,Owens GK.Vascular smooth muscle cells in atherosclerosis..Circ Res2016;118:692-702 PMCID:PMC4762053

[32] Misra A,Chandran RR.Integrin beta3 regulates clonality and fate of smooth muscle-derived atherosclerotic plaque cells..Nat Commun2018;9:2073 PMCID:PMC5970166

[33] Chappell J,Narasimhan VM.Extensive proliferation of a subset of differentiated, yet plastic, medial vascular smooth muscle cells contributes to neointimal formation in mouse injury and atherosclerosis models..Circ Res2016;119:1313-23 PMCID:PMC5149073

[34] Jacobsen K,Shim J.Diverse cellular architecture of atherosclerotic plaque derives from clonal expansion of a few medial SMCs..JCI Insight2017;2:95890 PMCID:PMC5841865

[35] Allahverdian S,Boukais K,Bochaton-Piallat ML.Smooth muscle cell fate and plasticity in atherosclerosis..Cardiovasc Res2018;114:540-50 PMCID:PMC5852505

[36] Allahverdian S,McManus BM,Francis GA.Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis..Circulation2014;129:1551-9

[37] Pryma CS,Dubland JA.Pathways of smooth muscle foam cell formation in atherosclerosis..Curr Opin Lipidol2019;30:117-24

[38] Zaid A,Essalmani R.Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration..Hepatology2008;48:646-54

[39] Ding Z,Wang X.Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta..Antioxid Redox Signal2015;22:760-71 PMCID:PMC4361218

[40] Ferri N,Pirillo A.Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels..Atherosclerosis2012;220:381-6

[41] Grune J,Bezhaeva T.PCSK9 regulates the chemokine receptor CCR2 on monocytes..Biochem Biophys Res Commun2017;485:312-8

[42] Ding Z,Wang X.Cross-talk between LOX-1 and PCSK9 in vascular tissues..Cardiovasc Res2015;107:556-67

[43] Liu S,Zhang P.Blood flow patterns regulate PCSK9 secretion via MyD88-mediated pro-inflammatory cytokines..Cardiovasc Res2020;116:1721-32

[44] Kühnast S,Pieterman EJ.Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin..J Lipid Res2014;55:2103-12 PMCID:PMC4174003

[45] Hajra L,Chen M,Collins T.The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation..Proc Natl Acad Sci USA2000;97:9052-7 PMCID:PMC16820

[46] Mittler R,Suzuki N.ROS signaling: the new wave?.Trends Plant Sci2011;16:300-9

[47] Li H,Förstermann U.Vascular oxidative stress, nitric oxide and atherosclerosis..Atherosclerosis2014;237:208-19

[48] Goncharov NV,Nadeev AD,Jenkins RO.Reactive oxygen species in pathogenesis of atherosclerosis..Curr Pharm Des2015;21:1134-46

[49] Xu S,Chen J,Moss J.LOX-1 in atherosclerosis: biological functions and pharmacological modifiers..Cell Mol Life Sci2013;70:2859-72 PMCID:PMC4142049

[50] Cominacini L,Garbin U.Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species..J Biol Chem2000;275:12633-8

[51] Sun H,Chang JT.PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction..J Lipid Res2018;59:207-23 PMCID:PMC5794417

[52] Quan Y,Tian G,Liu X.Mitochondrial ROS-modulated mtDNA: a potential target for cardiac aging..Oxid Med Cell Longev2020;2020:9423593 PMCID:PMC7139858

[53] Ding Z,Wang X,Dai Y.Oxidant stress in mitochondrial DNA damage, autophagy and inflammation in atherosclerosis..Sci Rep2013;3:1077 PMCID:PMC3546319

[54] Ricci C,Leonard J.Mitochondrial DNA damage triggers mitochondrial-superoxide generation and apoptosis..Am J Physiol Cell Physiol2008;294:C413-22

[55] Ding Z,Wang X.Cross-Talk between PCSK9 and damaged mtDNA in vascular smooth muscle cells: role in apoptosis..Antioxid Redox Signal2016;25:997-1008

[56] Zarubin T.Activation and signaling of the p38 MAP kinase pathway..Cell Res2005;15:11-8

[57] Wood CD,Sabio G,Rincon M.Nuclear localization of p38 MAPK in response to DNA damage..Int J Biol Sci2009;5:428-37 PMCID:PMC2702826

[58] Zhang Y,Zhang L.MicroRNA-26a prevents endothelial cell apoptosis by directly targeting TRPC6 in the setting of atherosclerosis..Sci Rep2015;5:9401 PMCID:PMC4371083

[59] Clarke MC,Maguire JJ.Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis..Nat Med2006;12:1075-80

[60] Wu CY,Jiang L,Jiang ZS.PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway..Mol Cell Biochem2012;359:347-58

[61] Li J,Wang Y,Li G.Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis..Mol Med Rep2017;16:1817-25 PMCID:PMC5561783

[62] Kim BJ,Song BJ.JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells..J Biol Chem2006;281:21256-65

[63] De Chiara G,Torcia M.Bcl-2 Phosphorylation by p38 MAPK: identification of target sites and biologic consequences..J Biol Chem2006;281:21353-61

[64] Breitschopf K,Malchow P,Dimmeler S.Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway..Mol Cell Biol2000;20:1886-96 PMCID:PMC85374

[65] Mäkinen PI,Heinonen SE.Silencing of either SR-A or CD36 reduces atherosclerosis in hyperlipidaemic mice and reveals reciprocal upregulation of these receptors..Cardiovasc Res2010;88:530-8

[66] Febbraio M,Silverstein RL.Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis..Arterioscler Thromb Vasc Biol2004;24:2333-8

[67] Febbraio M,Smith JD.Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice..J Clin Invest2000;105:1049-56 PMCID:PMC300837

[68] Podrez EA,Sheibani N.Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species..J Clin Invest2000;105:1095-108 PMCID:PMC300829

[69] Schuster S,Endres M.Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice..Sci Rep2019;9:11079 PMCID:PMC6668462

[70] Ding Z,Wang X.PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages..Cardiovasc Res2018;114:1145-53

[71] Adorni MP,Favari E.Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages..Atherosclerosis2017;256:1-6

[72] Silverstein RL.CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior..Sci Signal2009;2:re3 PMCID:PMC2811062

[73] Demers A,Lauzier B.PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver..Arterioscler Thromb Vasc Biol2015;35:2517-25

[74] Poirier S,Benjannet S.The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2..J Biol Chem2008;283:2363-72

[75] Badimon L,Crespo J,Borrell-Pages M.PCSK9 and LRP5 in macrophage lipid internalization and inflammation..Cardiovasc Res2020;cvaa254

[76] Ouimet M,Fisher EA.HDL and Reverse Cholesterol Transport..Circ Res2019;124:1505-18 PMCID:PMC6813799

[77] Bernelot Moens SJ,Kroon J.PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia..Eur Heart J2017;38:1584-93

[78] Drechsler M,Soehnlein O.Chemokines control mobilization, recruitment, and fate of monocytes in atherosclerosis..Arterioscler Thromb Vasc Biol2015;35:1050-5

[79] Ricci C,Camera M.PCSK9 induces a pro-inflammatory response in macrophages..Sci Rep2018;8:2267 PMCID:PMC5797178

[80] Tang Z,Peng J.PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages..Int J Mol Med2012;30:931-8

[81] Ding Z,Liu S.NLRP3 inflammasome via IL-1β regulates PCSK9 secretion..Theranostics2020;10:7100-10

[82] Feingold KR,Shigenaga JK,Grunfeld C.Inflammation stimulates the expression of PCSK9..Biochem Biophys Res Commun2008;374:341-4 PMCID:PMC2571081

[83] Liu L,Jiang Z.Effects of pcsk9 siRNA on THP-1 derived macrophages apoptosis induced by oxLDL..Prog Biochem Biophys2009;36:323-330

[84] Bai XQ,Wang MM.PCSK9: a potential regulator of apoE/apoER2 against inflammation in atherosclerosis?.Clin Chim Acta2018;483:192-6

[85] Kysenius K,Mätlik K,Huttunen HJ.PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling..Cell Mol Life Sci2012;69:1903-16

[86] Waltmann MD,Konaniah ES,Hui DY.Apolipoprotein E receptor-2 deficiency enhances macrophage susceptibility to lipid accumulation and cell death to augment atherosclerotic plaque progression and necrosis..Biochim Biophys Acta2014;1842:1395-405 PMCID:PMC4125478

[87] Saigusa R,Ley K.T cell subsets and functions in atherosclerosis..Nat Rev Cardiol2020;17:387-401

[88] Gil-Pulido J.Antigen-presenting dendritic cells in atherosclerosis..Eur J Pharmacol2017;816:25-31

[89] Liu A.PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque..J Intern Med2018;193-210

[90] Kim YU,Danila D.A critical role of PCSK9 in mediating IL-17-producing T cell responses in hyperlipidemia..Immune Netw2019;19:e41 PMCID:PMC6943168

[91] Taleb S,Mallat Z.IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles..Arterioscler Thromb Vasc Biol2015;35:258-64

[92] Huo Y,Forlow SB.Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E..Nat Med2003;9:61-7

[93] Lievens D.Platelets in atherosclerosis..Thromb Haemost2011;106:827-38

[94] Gurbel PA,Tantry US.Exploration of PCSK9 as a cardiovascular risk factor: is there a link to the platelet?.J Am Coll Cardiol2017;70:1463-6

[95] Pastori D,Farcomeni A.Relationship of PCSK9 and urinary thromboxane excretion to cardiovascular events in patients with atrial fibrillation..J Am Coll Cardiol2017;70:1455-62

[96] Tantry US,Gurbel PA.Aspirin resistance..Prog Cardiovasc Dis2009;52:141-52

[97] Navarese EP,Winter MP.Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the PCSK9-REACT study..Int J Cardiol2017;227:644-9

[98] Barale C,Frascaroli C.Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: a 12-month follow-up..Nutr Metab Cardiovasc Dis2020;30:282-91

[99] Camera M,Barbieri SS.PCSK9 as a positive modulator of platelet activation..J Am Coll Cardiol2018;71:952-4

[100] Wang N.Cholesterol in platelet biogenesis and activation..Blood2016;127:1949-53 PMCID:PMC4841038

[101] Ason B,Chan J.PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE..J Lipid Res2014;55:2370-9 PMCID:PMC4617138

[102] Qi Z,Zhang J.PCSK9(Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36..Circulation2021;143:45-61

[103] Yang M,Li W.Platelet CD36 promotes thrombosis by activating redox sensor ERK5 in hyperlipidemic conditions..Blood2017;129:2917-27 PMCID:PMC5445574

[104] Magwenzi S,Wraith KS.Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade..Blood2015;125:2693-703 PMCID:PMC4408294

[105] Podrez EA,Febbraio M.Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype..Nat Med2007;13:1086-95 PMCID:PMC3042888

[106] Kuijpers MJ,Nergiz-Unal R.Supporting roles of platelet thrombospondin-1 and CD36 in thrombus formation on collagen..Arterioscler Thromb Vasc Biol2014;34:1187-92

[107] Chen K,Li W.A specific CD36-dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein..Circ Res2008;102:1512-9 PMCID:PMC2749986

[108] Hackeng C,Pladet M,van Rijn H.Early platelet activation by low density lipoprotein via p38MAP kinase..Thromb Haemost2017;82:1749-56

[109] Cammisotto V,Nocella C.PCSK9 regulates Nox2-mediated platelet activation via CD36 receptor in patients with atrial fibrillation..Antioxidants (Basel)2020;9:296 PMCID:PMC7222182

[110] van der Laan AM,Delewi R.Monocyte subset accumulation in the human heart following acute myocardial infarction and the role of the spleen as monocyte reservoir..Eur Heart J2014;35:376-85 PMCID:PMC3916776

[111] Prabhu SD.The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis..Circ Res2016;119:91-112 PMCID:PMC4922528

[112] Miñana G,Bayés-Genís A.Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study..ESC Heart Fail2020;7:117-22 PMCID:PMC7083416

[113] Schlüter KD,Weber M,Schulz R.Oxidized low-density lipoprotein (oxLDL) affects load-free cell shortening of cardiomyocytes in a proprotein convertase subtilisin/kexin 9 (PCSK9)-dependent way..Basic Res Cardiol2017;112:63 PMCID:PMC5599470

[114] Yang CL,Hu ZX.PCSK9 promotes the secretion of pro-inflammatory cytokines by macrophages to aggravate H/R-induced cardiomyocyte injury via activating NF-κB signalling..Gen Physiol Biophys2020;39:123-34

[115] Ding Z,Liu S.PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy..Cardiovasc Res2018;114:1738-51

[116] Kim J,Viollet B.AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1..Nat Cell Biol2011;13:132-41 PMCID:PMC3987946

[117] Gui D,Zhang L.Salidroside attenuates hypoxia-induced pulmonary arterial smooth muscle cell proliferation and apoptosis resistance by upregulating autophagy through the AMPK-mTOR-ULK1 pathway..BMC Pulm Med2017;17:191 PMCID:PMC5726034

[118] Matsui Y,Qu X.Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy..Circ Res2007;100:914-22

[119] Angin Y,Simons PJ.CD36 inhibition prevents lipid accumulation and contractile dysfunction in rat cardiomyocytes..Biochem J2012;448:43-53

[120] Nagendran J,Kienesberger PC.Cardiomyocyte-specific ablation of CD36 improves post-ischemic functional recovery..J Mol Cell Cardiol2013;63:180-8

[121] Zhang Y,Dai M.Cardiospecific CD36 suppression by lentivirus-mediated RNA interference prevents cardiac hypertrophy and systolic dysfunction in high-fat-diet induced obese mice..Cardiovasc Diabetol2015;14:69 PMCID:PMC4464858

[122] Sung MM,Kim TT.Cardiomyocyte-specific ablation of CD36 accelerates the progression from compensated cardiac hypertrophy to heart failure..Am J Physiol Heart Circ Physiol2017;312:H552-60

[123] Abifadel M,Rabès JP.Mutations in PCSK9 cause autosomal dominant hypercholesterolemia..Nat Genet2003;34:154-6

[124] Robinson JG,Krempf M.Efficacy and safety of alirocumab in reducing lipids and cardiovascular events..N Engl J Med2015;372:1489-99

[125] Sabatine MS,Wiviott SD.Efficacy and safety of evolocumab in reducing lipids and cardiovascular events..N Engl J Med2015;372:1500-9